AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share

18 Dec 2025 19:17 CET

Issuer

AB SCIENCE

PRESS RELEASE

AB SCIENCE ANNOUNCES THE INITIATION OF COVERAGE OF ITS STOCK BY MAXIM GROUP WITH A TARGET PRICE OF EUR 4.0 PER SHARE

Paris, December 18, 2025, 7.15pm CET

AB Science SA (Euronext - FR0010557264 - AB) announces the initiation of coverage of its stock by Maxim Group, an independent US-based full-service investment bank, securities and wealth management firm.

Maxim Group began covering the stock with a study entitled “Mastering Mast Cell Inhibition for Neurodegenerative Diseases Starting with ALS”, published on 18 December 2025.

In this study, Maxim Group recommended buying the stock, with a target price of €4.00.

The study highlights that “Masitinib has generated promising benefits across three neurodegenerative diseases, which we believe validates the mast cell inhibition approach. Considering the underlying efficacy data and safety profile, we view the risk-benefit profile of masitinib as positive. Given the data and opportunity, we initiate coverage with a Buy rating and €4.00 price target. Positive data in progressive MS and in mild AD further supports its neuroprotective potential. We do not model AD or MS and consider them upside”.

This initiation completes the coverage of AB Science’s stock and adds to the financial analyst consensus alongside Chardan, In Extenso Finance and DNA Finance.

About AB Science

Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment.

AB Science has developed a proprietary portfolio of molecules and the Company’s lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Further information is available on AB Science’s website: www.ab-science.com.

Forward-looking Statements - AB Science

This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance.

These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations.

For additional information, please contact:

AB Science

Financial Communication & Media Relations

investors@ab-science.com

Attachment